JusticeItaly Official institution
Italy changes marketing permission for pregabalin medicine Regalbax
Italy's medicines agency AIFA issued a notice on 3 November 2026 about a change to the marketing permission for Regalbax, a human medicine containing pregabalin. The notice is identified by the reference number 26A05706. The document itself does not state what specific change was made, so the details must be checked at the source.
This summary was generated by AI; the official source prevails.
What does it mean?
Italy's medicines regulator has officially changed the permission under which Regalbax, a pain and nerve medicine containing pregabalin, can be sold. The notice does not say what exactly changed, so the full details are only in the official document.
Who is affected?
Patients who use Regalbax and the companies that sell or supply it in Italy.